Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimicotinib - Abbisko Therapeutics

Next Previous
Drug Profile

Pimicotinib - Abbisko Therapeutics

Alternative Names: ABSK-021

Latest Information Update: 08 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbisko Therapeutics
  • Developer Abbisko Therapeutics; Merck AG; Sperogenix Therapeutics
  • Class Amides; Antineoplastics; Ethers; Pyrazoles; Pyridines; Pyrrolidinones; Small molecules
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Giant cell tumour of tendon sheath
  • Phase III Solid tumours
  • Phase II Graft-versus-host disease; Pancreatic cancer
  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 30 Mar 2026 Merck Healthcare KGaA plans a phase II J-MANEUVER trial for Giant cell tumour of tendon sheath (Inoperable/Unresectable) in Germany (PO) in April 2026 (NCT07499362)
  • 26 Mar 2026 Phase-II clinical trials in Giant cell tumour of tendon sheath (Inoperable/Unresectable) in Japan (PO) (NCT07499362)
  • 13 Jan 2026 Preregistration for Giant cell tumour of tendon sheath (Inoperable/Unresectable, Late-stage disease) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top